Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million
I'm PortAI, I can summarize articles.
Biofrontera AG reported a 14.8% increase in group sales to EUR 12.3 million for the first nine months of 2025. EBITDA rose to EUR 1.8 million from a previous loss, and EBIT reached EUR 1.2 million. Sales to Biofrontera Inc. were EUR 3.1 million, with European sales up 7.5%. Distribution costs decreased to EUR 4.7 million, but the financial result was negative EUR 0.1 million, and net income after taxes was negative EUR 4.1 million.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments